Real-world study tracks blood cancer patients on zanubrutinib

NCT ID NCT05326308

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 24 times

Summary

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib. Researchers want to see how the drug affects quality of life and how often patients need hospital care. The study does not test a new treatment but gathers information from real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lübecker Onkologische Schwerpunktpraxis

    RECRUITING

    Lübeck, Schleswig-Holstein, D-23562, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Salzburg, Klinik für Innere Medizin III

    RECRUITING

    Salzburg, A-5020, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.